Regado Biosciences (Regado Biosciences) Margin of Safety % (DCF FCF Based) : N/A (As of May. 16, 2024)

View and export this data going back to . Start your Free Trial

What is Regado Biosciences Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Regado Biosciences's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Regado Biosciences's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Regado Biosciences's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regado Biosciences's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regado Biosciences's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Regado Biosciences's Margin of Safety % (DCF FCF Based) falls into.

Regado Biosciences Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Regado Biosciences's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Regado Biosciences (Regado Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regado Biosciences Inc (NAS:RGDO) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.tobiratherapeutics.com

Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.

Executives

Domain Parters Vii L P	10 percent owner	ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Associates Domain	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Dp Vi Associates, L.p.	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Brian K Halak	10 percent owner	C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Kim P. Kamdar	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber	director	C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Patrick J Heron	director	550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Dp Vii Associates Lp	10 percent owner	ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Jeffrey H Cooper	director	BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Frazier Healthcare V, Lp	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Christopher Peetz	officer: Chief Financial Officer	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Andrew J. Fromkin	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
Carol L Brosgart	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Regado Biosciences (Regado Biosciences) Headlines

No Headlines